论文部分内容阅读
观察卡斯迈欣片治疗呼吸道革兰阳性菌感染的疗效及安全性。方法：将６０例患者随机分成两组，一组（３０例）服用治疗药卡斯迈欣片，另一组（３０例）服用对照药克拉仙片。比较两组的有效率及不良反应发生率。结果：两组的疗效及安全性差异均无显著性，卡斯迈欣片的临床痊愈率、临床有效率、痰菌阴转率和痰菌消除率分别为６０．０％，９３．３％，９６．０％和９６．０％，不良反应发生率为６．７％。５１株临床分离菌的体外敏感性试验显示，卡斯迈欣对多数革兰阳性病原菌有良好的抗菌活性。结论：卡斯迈欣片治疗呼吸道革兰阳性菌感染疗效确切，不良反应少见而轻微，其疗效和安全性与克拉仙片相仿。
To observe the efficacy and safety of Kasimasin tablets in the treatment of respiratory Gram-positive bacterial infections. Methods: Sixty patients were randomly divided into two groups. One group (30 cases) took Kasimin tablets and the other group (30 cases) took control tablets. Compare the two groups of the efficiency and incidence of adverse reactions. Results: There was no significant difference in efficacy and safety between the two groups. The clinical cure rate, clinical effective rate, sputum negative conversion rate and sputum elimination rate of Kasimaxin tablets were 60.0% and 93.3% , 96.0% and 96.0%, the incidence of adverse reactions was 6.7%. In vitro susceptibility tests of 51 strains of clinical isolates showed that Kasimaixin had good antibacterial activity against most Gram-positive pathogens. Conclusion: Kasimin tablet treatment of respiratory infections caused by Gram-positive bacteria, the adverse reactions are rare and mild, its efficacy and safety and Kla 仙片 similar.